| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8744953 | Clinical Microbiology and Infection | 2018 | 12 Pages |
Abstract
As there are limited clinical data for many of the reviewed agents, special attention must be given to promptly detect and report emerging infectious complications.
Related Topics
Life Sciences
Immunology and Microbiology
Microbiology
![ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Agents targeting lymphoid cells surface antigens [I]: CD19, CD20 and CD52)](/preview/png/8744953.png "First Page Preview: ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Agents targeting lymphoid cells surface antigens [I]: CD19, CD20 and CD52)")
Authors
M. Mikulska, S. Lanini, C. Gudiol, L. Drgona, G. Ippolito, M. Fernández-Ruiz, B. Salzberger,